Key result
Cardiac resynchronization therapy reduces morbidity and mortality in heart failure, though uncertainty remains on how to accurately identify responders and manage patients following device implant.
Cardiac resynchronization therapy is an established treatment for heart failure to reduce morbidity and mortality, though uncertainty remains regarding optimal patient selection and post-implant management.
Supports CRT in eligible HF patients; leaves open optimal responder selection and post-implant management.
Heart failure is posing an increasing burden on healthcare systems around the world, a consequence of increased survival from acute coronary syndromes and life-prolonging medications. Cardiac resynchronization therapy has become a ratified and established therapy for heart failure to reduce both the morbidity and mortality of the condition. Its prophylactic role in patients who have minimal symptoms to delay future deterioration is a novel development. The indications for this therapy continue to evolve, mainly as a result of company-sponsored multicenter trial data aimed at broadening its usage. Uncertainty remains on how to accurately identify individuals who will respond to resynchronization therapy and how best to manage patients following device implant.
No takes yet. Share an insight, caveat, or question.
Nayar et al. (2010) conducted a review in Heart failure. Cardiac resynchronization therapy was evaluated. Cardiac resynchronization therapy reduces morbidity and mortality in heart failure, though uncertainty remains on how to accurately identify responders and manage patients following device implant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: